BIOSTAT-CHF
Facilitate personalized therapies in patients with heart failure
BIOSTAT-CHF
BIOSTAT-CHF is a EU-funded large scale project with the main aim to facilitate personalized therapies in patients with heart failure. BIOSTAT-CHF stands for: A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure.
We use several artificial intelligence applications (such as network/pathway analyses, cluster analyses, machine learning en system biology) using large scale -omics data (genomics, proteomics, transcriptomics, and biomarkers) to get a better insight in the pathophysiology of specific groups of patients with heart failure, leading to better and more personalized therapies of patients with heart failure.
From 2010-2015 data from 2 large cohorts of patients with heart failure ( n=2516 and n=1738) were collected and information on clinical outcome was captured. During a median of 21 months, 45% of patients died or had to be hospitalized for worsening of heart failure, indicating the severity of this disease.
From 2015 – now, a large group of researchers have performed various analyses and in the meantime more than 50 papers are published from this project, all of which were published in Q1 journals.
We are currently looking for PhD students and post-docs, both medical doctors, (medical) biologists and statisticians and bio-informaticians to support future studies to learn more about pathways related to disease progression, with specific attention to sex-differences, atrial fibrillation, diabetes and the differences between patients with heart failure with preserved and reduced ejection fraction (HFpEF versus HFrEF)
“A large group of researchers have performed various analyses and in the meantime more than 50 papers are published from this project”
People involved
Team
International collaborations
- Prof. Stefan D. Anker, Berlin , Germany
- Prof John G. Cleland. Glasgow, UK
- Prof. Kenneth Dickstein, Stavanger, Norway
- Prof. Gerasimos Filippatos, Athens, Greece
- Prof. Chim C. Lang, Dundee, UK
- Prof. Leong Ng, Leicester, UK
- Prof. Piotr Ponikowski, Wroclaw, Poland
- Prof. Nilesh J. Samani. Leicester, UK
- Prof. Faiez Zannad, Nancy, France
- Prof. Marco Metra, Brescia, Italy
- Prof. Carolyn Lam. Singapore
Awards and funding
Funded by the European Research Council (ERC)
read morePress & publications
Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, ASIAN-HF investigators, Voors AA. Lancet 2019
view on publisher siteNovel endotypes in heart failure: effects on guideline-directed medical therapy.
Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P. Eur Heart J. 2018
view on publisher siteIdentifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.
Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA. J Am Coll Cardiol. 2018
view on publisher siteComparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA. Eur Heart J 2018
view on publisher siteDeterminants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH. Eur Heart J. 2017
view on publisher sitePress: Heart failure patients consuming more protein live longer
Heart failure patients who have a higher protein intake live longer, according to new research presented at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology (ESC) congress.
Read the articlePress: Heart failure patients with a higher protein intake live longer
Heart failure patients who consume more protein live longer, according to research presented today at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress.
Read the articlePress: High-protein diet can help heart patients to survive
Patients with heart failure who eat more protein live longer, according to a study.
Read the articlePress: Vrouwen kunnen na hartfalen toe met lagere dosis medicijnen (only in Dutch)
De optimale dosering van medicatie voor vrouwen met hartfalen ligt aanzienlijk lager dan voor mannen. Dat blijkt uit een internationaal onderzoek onder leiding van het Universitair Medisch Centrum Groningen dat is verschenen in het wetenschappelijke toptijdschrift The Lancet.
Read the article
